Targanta Initiates Phase 2 Oritavancin Infrequent Dosing Study
SIMPLIFI to Examine Single-Dose and Infrequent-Dosing Regimens in cSSSI
CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Targanta Therapeutics
Corporation today announced the initiation of its Phase 2 trial
investigating the safety and efficacy of oritavancin
at Single or
Infrequent Doses for the Tr...
Targanta Reports Improved Ability of Oritavancin to Stop Bacteria
Growth In Vitro Compared With Other Glycopeptide Antibiotics
Studies Presented at ECCMID/ICC
MUNICH, Germany, April 03, 2007 /PRNewswire/ -- Targanta
Therapeutics today announced results from two studies showing the
improved potency of oritavancin
to stop bacterial growth in vitro
when tested with a common wetting agent (polysorbate 80) an...
Targanta Study Shows Oritavancin Treatment Effective in a Mouse
Model of Anthrax
Single-Dose Protection Observed Prior to or Up to 24 Hours After
Exposure to Anthrax
TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- Targanta
Therapeutics Corporation announced today the results from a recent
study demonstrating oritavancin
as a potential therapy for treating
exposure to Bacillus a...
Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
...rom hospital sites in the
U.S., Europe and Israel. oritavancin
was active against all staphylococcal
isolates, in...ter E-1613, entitled "In Vitro Activity Profile of oritavancin
Against Organisms Demonstrating Key Resistan...er
Antimicrobial Agents," compared the activity of oritavancin
and teicoplanin against a diverse co...
Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Oritavancin," researchers tested the activity of oritavancin
standards of care, metronidazole and va...ntitled "Activity of Metronidazole, Vancomycin and oritavancin
Epidemic Clostridium difficile Spores," re...tal methods,
results from the study indicated that oritavancin
interacts with and
disrupts the transition from do...